Detalhe da pesquisa
1.
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
Blood
; 141(8): 917-929, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36356299
2.
Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs.
Blood
; 140(11): 1291-1304, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35763665
3.
Evaluation of the ATM L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms.
Haematologica
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38654656
4.
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Ann Hematol
; 103(2): 437-442, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38060001
5.
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning.
Blood
; 135(4): 287-292, 2020 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697803
6.
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
Blood
; 135(2): 133-144, 2020 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697806
7.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
Blood
; 135(5): 381-386, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869407
8.
PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.
Am J Hematol
; 97(4): 390-400, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015307
9.
Primary Budd-Chiari Syndrome.
N Engl J Med
; 389(8): 769, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37611130
10.
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.
Blood
; 134(2): 199-210, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31064751
11.
Myeloproliferative and lymphoproliferative disorders: State of the art.
Hematol Oncol
; 38(2): 121-128, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31833567
12.
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib.
Hematol Oncol
; 38(4): 554-559, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32583904
13.
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.
Ann Hematol
; 99(1): 65-72, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31832751
14.
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.
Am J Hematol
; 95(2): 156-166, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31721282
15.
Second cancers in MPN: Survival analysis from an international study.
Am J Hematol
; 95(3): 295-301, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31816122
16.
The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance.
Int J Mol Sci
; 21(23)2020 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33255170
17.
A journey through infectious risk associated with ruxolitinib.
Br J Haematol
; 187(3): 286-295, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31468506
18.
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Blood
; 129(6): 680-692, 2017 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28028026
19.
Clinical significance of somatic mutation in unexplained blood cytopenia.
Blood
; 129(25): 3371-3378, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28424163
20.
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms.
Blood
; 139(17): 2716-2720, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35100354